SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Wojdyla Daniel M.))
 

Sökning: (WFRF:(Wojdyla Daniel M.)) > (2015-2019) > Clinical consequenc...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004278naa a2200373 4500
001oai:DiVA.org:uu-393326
003SwePub
008190927s2019 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3933262 URI
0247 a https://doi.org/10.1016/j.ahj.2019.05.0042 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Sharma, Abhinavu Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC USA;McGill Univ, Div Cardiol, Hlth Ctr, Montreal, PQ, Canada;Stanford Univ, Div Cardiol, Stanford Sch Med, Stanford, CA 94305 USA4 aut
2451 0a Clinical consequences of bleeding among individuals with a recent acute coronary syndrome :b Insights from the APPRAISE-2 trial
264 1b MOSBY-ELSEVIER,c 2019
338 a print2 rdacarrier
520 a Background Patients with a recent acute coronary syndrome (ACS) receiving oral antiplatelets and anticoagulants are at risk for bleeding and subsequent adverse non-bleeding-related events. Methods In this post hoc analysis, we evaluated 7,392 high-risk patients (median follow-up 241 days) with a recent ACS randomized to apixaban or placebo in APPRAISE-2. Clinical events during a 30-day period after Thrombolysis in Myocardial Infarction (TIMI) major/minor bleeding were analyzed using unadjusted and adjusted Cox proportional-hazards models. Results In total, 153 (2.1%) patients experienced TIMI major/minor bleeding during follow-up. Bleeding risk for patients on triple therapy (apixaban, thienopyridine, and aspirin) was increased compared with those on dual therapy (apixaban plus aspirin: hazard ratio [HR] 2.02, 95% CI 1.08-3.79; thienopyridine plus aspirin: HR 1.99, 95% CI 1.41-2.83). Those receiving apixaban/aspirin had similar bleeding risk compared with those receiving thienopyridine/aspirin (HR 1.01, 95% CI 0.53-1.95). Patients who experienced TIMI major/minor bleeding had an increased risk of 30-day all-cause mortality (HR 24.7, 95% CI 15.34-39.66) and ischemic events (HR 6.7, 95% CI 3.14-14.14). Conclusions In a contemporary cohort of high-risk patients after ACS, bleeding was associated with a significantly increased risk of subsequent ischemic events and mortality regardless of antithrombotic or anticoagulant strategy. Patients receiving apixaban plus aspirin had a similar bleeding risk compared with those receiving thienopyridine plus aspirin. Interventions to improve outcomes in patients after ACS should include strategies to optimize the reduction in ischemic events while minimizing the risk of bleeding.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
7001 a Hagström, Emilu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Institutionen för medicinska vetenskaper4 aut0 (Swepub:uu)emhag677
7001 a Wojdyla, Daniel M.u Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC USA4 aut
7001 a Neely, Megan L.u Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC USA4 aut
7001 a Harrington, Robert A.u Stanford Univ, Div Cardiol, Stanford Sch Med, Stanford, CA 94305 USA4 aut
7001 a Wallentin, Lars,d 1943-u Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Institutionen för medicinska vetenskaper4 aut0 (Swepub:uu)larswall
7001 a Alexander, John H.u Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC USA4 aut
7001 a Goodman, Shaun G.u Univ Toronto, St Michaels Hosp, Terrence Donnelly Heart Ctr, Toronto, ON, Canada4 aut
7001 a Lopes, Renato D.u Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC USA4 aut
7102 a Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC USA;McGill Univ, Div Cardiol, Hlth Ctr, Montreal, PQ, Canada;Stanford Univ, Div Cardiol, Stanford Sch Med, Stanford, CA 94305 USAb Uppsala kliniska forskningscentrum (UCR)4 org
7730 t American Heart Journald : MOSBY-ELSEVIERg 215, s. 106-113q 215<106-113x 0002-8703x 1097-6744
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-393326
8564 8u https://doi.org/10.1016/j.ahj.2019.05.004

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy